Eisai’s Halaven Injection gets FDA approval to treat advanced liposarcoma

The US Food and Drug Administration (FDA) has granted approval for Eisai's Halaven (eribulin mesylate) Injection (0.5mg/mL) to treat patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news